Efficacy assessment of diverse antibiotic combinations in bismuth quadruple regimens and risk factors for Helicobacter pylori eradication: a retrospective single-center study in China

被引:0
|
作者
Li, Zhen [1 ]
Dong, Zhao-Jing [2 ]
Ding, Hai-Ou [3 ]
Gao, Hong-Jie [3 ]
Cheng, Jian-Ping [1 ]
机构
[1] Civil Aviat Gen Hosp, Dept Gastroenterol & Oncol, 76 Chaoyang Rd, Beijing 100123, Peoples R China
[2] Civil Aviat Gen Hosp, Dept Med Record, Beijing, Peoples R China
[3] Civil Aviat Gen Hosp, Dept Pharm, Beijing, Peoples R China
关键词
Helicobacter pylori; quadruple therapy; antibiotic combinations; bismuth; eradication rate; DUAL THERAPY; VONOPRAZAN; RABEPRAZOLE; OMEPRAZOLE; INFECTION; 1ST-LINE; SMOKING; TRIAL;
D O I
10.62347/SMLE6245
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: To evaluate the efficacy of various antibiotic combinations in bismuth quadruple therapy for H. pylori eradication. Methods: This study involved a retrospective analysis of data collected from a single medical center in Beijing, China. A cohort of patients was enrolled with H. pylori infection that underwent 14-d bismuth quadruple therapy (antibiotics, omeprazole, and bismuth) and received a test for cure between January 2020 and December 2023. Patient demographics and therapeutic regimens were meticulously compiled and subsequently categorized into five groups based on antibiotic combinations used: amoxicillin-clarithromycin, amoxicillin-levofloxacin, amoxicillin-doxycycline, clarithromycin-levofloxacin, and clarithromycin-doxycycline. The eradication rates were then calculated and compared across these distinct regimens. Results: This study evaluated a cohort of 575 patients, comprising 261 males and 314 females. A significant majority of patients, 76.3% (n=439), received a treatment regimen comprising amoxicillin and clarithromycin. The amoxicillin-levofloxacin combination was administered to 8.5% (n=49) of the patients. A smaller proportion, 1.7% (n=10), were treated with an amoxicillin-doxycycline regimen. Furthermore, 8.9% (n=51) of the patients received a clarithromycin-levofloxacin regimen, while 4.5% (n=26) were treated with a combination of clarithromycin and doxycycline. Patients treated with the amoxicillin-doxycycline-based regimen exhibited significantly higher eradication rates than other regimens (70.0% vs 65.4%, 32.7%, 54.9%, and 42.3%, respectively; P=0.001). Furthermore, the results indicated that risk factors such as smoking and alcohol consumption had a significant impact on the eradication rates (all P<0.01). Conclusion: This study reveals significant differences in the eradication rates of various antibiotic combinations for H. pylori infection. Of particular note is that the amoxicillin-doxycycline-based regimen outperformed other antibiotic combinations, with a considerably higher eradication rate. This provides vital insight to inform clinical decision-making in the treatment of H. pylori.
引用
收藏
页码:75 / 83
页数:9
相关论文
共 50 条
  • [1] Real-World Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study
    Cheng, Jianping
    Fan, Chanjuan
    Li, Zhen
    Dong, Zhaojing
    Zhao, Xiaolin
    Cai, Yong
    Ding, Haiou
    Dou, Yan
    Zhang, Xiaomei
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2024, 17 : 191 - 200
  • [2] Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori
    Wang, Junxian
    Cao, Yuping
    He, Wei
    Li, Xiaoping
    MEDICINE, 2021, 100 (51) : E28323
  • [3] Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication
    Lee, Jung Won
    Kim, Nayoung
    Nam, Ryoung Hee
    Lee, Sun Min
    Soo In, Choi
    Kim, Jung Mogg
    Lee, Dong Ho
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (04) : 666 - 672
  • [4] Comparison of Sequential, Hybrid, and Quadruple Therapy Protocols in Helicobacter pylori Eradication: A Single-Center Study
    Kuloglu, Ersin
    Albayrak, Bulent
    Dursun, Hakan
    Albayrak, Fatih
    Yilmaz, Omer
    EURASIAN JOURNAL OF MEDICINE, 2022, 54 (03): : 235 - 238
  • [5] Helicobacter pylori Eradication: A Single-Center Quality Improvement Study
    Parekh, Ravish
    El Atrache, Mazen
    Schiesser, Rachel
    del Castillo, Eduardo Castillo
    Alaradi, Osama
    GASTROENTEROLOGY, 2013, 144 (05) : S336 - S337
  • [6] Prevalence of Helicobacter pylori Infection and Efficacy of Bismuth Quadruple and Levofloxacin Triple Eradication Therapies: A Retrospective Analysis
    Serena, Patricia
    Popa, Alexandru
    Bende, Renata
    Miutescu, Bogdan
    Mare, Ruxandra
    Borlea, Andreea
    Aragona, Giovanni
    Groza, Andrei Lucian
    Serena, Luca
    Popescu, Alina
    Sporea, Ioan
    Sirli, Roxana
    LIFE-BASEL, 2024, 14 (07):
  • [7] The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study
    He, Xiao-Jian
    Wang, Xiao-Ling
    Sun, Dong-Jie
    Huang, Xiao-Yan
    Liu, Gang
    Li, Da-Zhou
    Lin, Hai-Lan
    Zeng, Xiang-Peng
    Li, Dong-Liang
    Wang, Wen
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [8] Helicobacter pylori Antibiotic Resistance in Egypt: A Single-Center Study
    Metwally, Mohamed
    Ragab, Raghda
    Hamid, Hasnaa S. Abdel
    Emara, Nashwa
    Elkholy, Hany
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 5905 - 5913
  • [9] Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real-world evidence
    He, Qiyunna
    Ou, Yan
    Zhu, Huili
    Chen, Zhiqian
    Yang, Dailan
    Cheng, Qian
    Yin, Xia
    Xiao, Lina
    Cai, Lin
    Ye, Yan
    Xu, Xin
    Liao, Juan
    JGH OPEN, 2024, 8 (05):
  • [10] Efficacy and safety of modified tetracycline dosing in a quadruple therapy for Helicobacter pylori: A retrospective single center study
    Ying-Chao Sun
    Meng-Jia Zhu
    Xue-Qin Chen
    Lei Yue
    Yi-Ru Zhao
    Xin-Jie Wang
    John J Kim
    Qin Du
    Wei-Ling Hu
    World Journal of Gastroenterology, 2023, (22) : 3508 - 3518